In a recently published study, researchers from the Max Planck Institute for Dynamics and Self-Organization in Germany, the University of Cologne, and the University of Washington found that a carefully designed mixtureRead More…
The latest update— Cases of COVID-19 in the U.S. at a Glance on April 3, 2020, which include both confirmed and presumptive positive cases of COVID-19 reported to CDC or tested atRead More…
In 2012, MERS-CoV (Middle East Respiratory Syndrome Coronavirus) was found in Saudi Arabia. The early labor symptoms caused by the viruse are similar to SARS (Severe Acute Respiratory Syndrome). Therefore, MERS-CoV isRead More…
As we all know, a new crown pneumonia epidemic suddenly swept China at the end of 2019 and even affected the whole world. On January 30, 2020, WHO announced that the epidemicRead More…
In 2002, severe acute respiratory syndrome occurred in Guangdong, China, and spread throughout the world, causing a global epidemic of infectious diseases. The culprit of this incident was SARS-CoV (Severe Acute RespiratoryRead More…
Recently, a virus called SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) caused an epidemic with pneumonia as the main symptom. This SARS-CoV-2 is a coronavirus, so what exactly is a coronavirus? OverviewRead More…
Checkpoint inhibitor drugs, those that pull the brakes off the immune system, can cause dramatic improvements in cancer patients, but the benefits are far from universal. In the case of atezolizumab (Tecentriq),Read More…
“A new article outlines a pioneering method of screening a person’s diverse set of antibodies for rapid therapeutic discovery. Antibody proteins are an important part of the human immune system that specificallyRead More…
Keytruda (pembrolizumab) is a drug developed by Merck (or MSD outside of the U.S. and Canada). It has been approved by the U.S. Food and Drug Administration (FDA) and the European Commission for the treatment of aRead More…
“Emicizumab (trade name Hemlibra, emicizumab–kxwh, ACE910, RO5534262) is a bispecific IgG4 mAb targeting Factors IXa and X. On November 16, 2017, the drug (emicizumab–kxwh) was approved by Food and Drug Administration (FDA) approved to preventRead More…